The Impact of Antimicrobial Resistance on Health and Economic Outcomes
Top Cited Papers
Open Access
- 1 June 2003
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 36 (11), 1433-1437
- https://doi.org/10.1086/375081
Abstract
Despite an increasing prevalence of antimicrobial-resistant pathogens, the health and economic impact of colonization and infection with these organisms has not been fully elucidated. We explore how antimicrobial resistance can affect patient outcomes by enhancing virulence, causing a delay in the administration of appropriate therapy, and limiting available therapy. Next, we examine the different perspectives held by hospitals, third-party payers, patients, and society on the impact of resistance. Finally, we review methodological issues in designing and assessing studies that address the clinical outcomes for patients infected or colonized with resistant pathogens, including adjustment for important confounding variables, control group selection, and the quantification of economic outcomes.Keywords
This publication has 24 references indexed in Scilit:
- Health and Economic Outcomes of the Emergence of Third-Generation Cephalosporin Resistance in Enterobacter SpeciesArchives of Internal Medicine, 2002
- National Nosocomial Infections Surveillance (NNIS) System Report, Data Summary from January 1992-June 2001, Issued August 2001American Journal of Infection Control, 2001
- Extended-Spectrum -Lactamase-Producing Escherichia coli and Klebsiella pneumoniae: Risk Factors for Infection and Impact of Resistance on OutcomesClinical Infectious Diseases, 2001
- The cost of antibiotic resistance from a bacterial perspectiveDrug Resistance Updates, 2000
- The Influence of Inadequate Antimicrobial Treatment of Bloodstream Infections on Patient Outcomes in the ICU SettingSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 2000
- Effects of Environment on Compensatory Mutations to Ameliorate Costs of Antibiotic ResistanceScience, 2000
- Health and Economic Outcomes of Antibiotic Resistance in Pseudomonas aeruginosaArchives of Internal Medicine, 1999
- Intravenous Colistin as Therapy for Nosocomial Infections Caused by Multidrug‐Resistant Pseudomonas aeruginosa and Acinetobacter baumanniiClinical Infectious Diseases, 1999
- Inadequate Antimicrobial Treatment of InfectionsSocial psychiatry. Sozialpsychiatrie. Psychiatrie sociale, 1999
- Slow Response to Vancomycin or Vancomycin plus Rifampin in Methicillin-resistant Staphylococcus aureus EndocarditisAnnals of Internal Medicine, 1991